| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,990,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Tenaya Therapeutics is a biotechnology company focused on discovering, designing, developing and delivering curative therapies that address the underlying drivers of heart disease. Co. is improving a pipeline of disease-modifying therapies developed using Co.'s product platforms and primary internal capabilities to target defined sub-populations of patients with prevalent forms of heart disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
71,428,568 |
75,873,012 |
| Total Buy Value |
$0 |
$0 |
$49,999,998 |
$69,999,996 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
4 |
| Total Shares Sold |
7,370 |
29,918 |
57,055 |
109,203 |
| Total Sell Value |
$9,802 |
$38,054 |
$51,945 |
$299,905 |
| Total People Sold |
3 |
3 |
3 |
6 |
| Total Sell Transactions |
3 |
6 |
12 |
21 |
| End Date |
2025-11-13 |
2025-08-12 |
2025-02-11 |
2024-02-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Svennilson Peter |
|
– – • |
2026-02-11 |
4 |
S |
$0.68 |
$2,761,715 |
I/I |
(4,056,573) |
2,651,817 |
|
- |
|
| Svennilson Peter |
|
– – • |
2026-02-10 |
4 |
S |
$0.82 |
$280,507 |
I/I |
(343,717) |
4,803,275 |
|
- |
|
| Higa Tomohiro |
SVP, Finance |
• – – |
2026-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
29,250 |
123,221 |
|
- |
|
| Ali Faraz |
Chief Executive Officer |
• • – |
2026-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
158,600 |
458,266 |
|
- |
|
| Tingley Whittemore |
Chief Medical Officer |
• – – |
2026-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
48,750 |
223,778 |
|
- |
|
| Tingley Whittemore |
Chief Medical Officer |
• – – |
2025-11-17 |
4 |
S |
$1.33 |
$3,826 |
D/D |
(2,877) |
169,926 |
|
- |
|
| Higa Tomohiro |
SVP, Finance |
• – – |
2025-11-17 |
4 |
S |
$1.33 |
$1,818 |
D/D |
(1,367) |
93,971 |
|
- |
|
| Ali Faraz |
Chief Executive Officer |
• • – |
2025-11-17 |
4 |
S |
$1.33 |
$4,158 |
D/D |
(3,126) |
299,666 |
|
- |
|
| Tingley Whittemore |
Chief Medical Officer |
• – – |
2025-08-18 |
4 |
S |
$1.25 |
$6,331 |
D/D |
(5,053) |
172,803 |
|
- |
|
| Ali Faraz |
Chief Executive Officer |
• • – |
2025-08-18 |
4 |
S |
$1.25 |
$18,210 |
D/D |
(14,533) |
302,792 |
|
- |
|
| Higa Tomohiro |
SVP, Finance |
• – – |
2025-08-18 |
4 |
S |
$1.25 |
$3,711 |
D/D |
(2,962) |
95,338 |
|
- |
|
| Ali Faraz |
Chief Executive Officer |
• • – |
2025-05-16 |
4 |
S |
$0.44 |
$1,412 |
D/D |
(3,189) |
317,325 |
|
- |
|
| Higa Tomohiro |
SVP, Finance |
• – – |
2025-05-16 |
4 |
S |
$0.44 |
$615 |
D/D |
(1,390) |
98,300 |
|
- |
|
| Tingley Whittemore |
Chief Medical Officer |
• – – |
2025-05-16 |
4 |
S |
$0.44 |
$1,300 |
D/D |
(2,937) |
171,856 |
|
- |
|
| Higa Tomohiro |
SVP, Finance |
• – – |
2025-03-10 |
4 |
S |
$0.54 |
$1,336 |
D/D |
(2,482) |
99,690 |
|
- |
|
| Tingley Whittemore |
Chief Medical Officer |
• – – |
2025-03-10 |
4 |
S |
$0.54 |
$3,983 |
D/D |
(7,398) |
174,793 |
|
- |
|
| Ali Faraz |
Chief Executive Officer |
• • – |
2025-03-10 |
4 |
S |
$0.54 |
$5,245 |
D/D |
(9,741) |
320,514 |
|
- |
|
| Tcg Opportunity Iii Gp, Llc |
|
– – • |
2025-03-05 |
4 |
B |
$0.70 |
$24,999,999 |
I/I |
35,714,284 |
49,313,559 |
0.01 |
- |
|
| Goeddel David V |
|
– • • |
2025-03-05 |
4 |
B |
$0.70 |
$24,999,999 |
I/I |
35,714,284 |
49,313,559 |
0.01 |
- |
|
| Higa Tomohiro |
SVP, Finance |
• – – |
2025-02-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
102,172 |
|
- |
|
| Ali Faraz |
Chief Executive Officer |
• • – |
2025-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
141,924 |
330,255 |
|
- |
|
| Tingley Whittemore |
Chief Medical Officer |
• – – |
2025-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
71,676 |
178,782 |
|
- |
|
| Saito Chihiro |
SVP, Accounting and Fin. Ops. |
• – – |
2024-08-16 |
4 |
S |
$2.89 |
$6,840 |
D/D |
(2,363) |
63,241 |
|
- |
|
| Ali Faraz |
Chief Executive Officer |
• • – |
2024-08-16 |
4 |
S |
$2.89 |
$28,216 |
D/D |
(9,748) |
188,331 |
|
- |
|
| Tingley Whittemore |
Chief Medical Officer |
• – – |
2024-08-16 |
4 |
S |
$2.89 |
$21,500 |
D/D |
(7,428) |
107,106 |
|
- |
|
69 Records found
|
|
Page 1 of 3 |
|
|
